Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Appendix B Biographical Sketches Philip Brachman, M.D. (Chair), is currently Professor, Department of International Health, Rollins School of Public Health (RSPH), Emory University. He joined the CDC in 1954 and worker! in epidemiology and training until his retirement in 1986. He held positions in the Bu- reau of Epidemiology, and then the Epidemiology Program Office, which he directed from 1970 to 1981. Dr. Brachman also directed the Field Epidemiology Training Program until 1986. He subsequently joined the RSPH faculty and is primarily involves! in teaching regular courses in epidemiology anti biostatistics in Atlanta and overseas. Dr. Brachman's current research activi- ties include public health surveillance and nosocomial infections. He also directs the Hubert H. Humphrey Fellowship program, a scholarship program financed by the U.S. government for for- eign professionals to study and work for one year in the United States. Adaora Alise Adimora, M.D., M.PH., is an Assistant Professor of Medicine and Clinical Assis- tant Professor of Epiclemiology at the University of North Carolina School of Medicine in Chapel Hill. Her work has included efficacy trials of a herpes simplex vaccine, studies of HIV epidemiology in minority populations, and AIDS training in international settings. She also served on the FDA's Vaccines and Related Biological Products Advisory Committee. Trudy Bush, Ph.D., M.H.S., was Professor and Director of the Graduate Program in the De- partment of Epidemiology and Preventive Medicine at the University of Marylanc} School of Medicine through March 2001. She was a cardiovascular epidemiologist by training, and her work focused on two primary areas: the epidemiology of cardiovascular disease in women and in older people and the effects of exogenous hormones on disease risk in women. Theodore C. Eickhoff, M.D., is Professor of Medicine in the Division of Infectious Disease' University of Coloraclo Health Sciences Center. He has expertise in internal medicine, infectious diseases, and epidemiology. He has long been interested in disease prevention by immunization, and has been an advocate of improved immunization of adults. He has served on the Advisory Committee on Immunization Practices, the National Vaccine Advisory Committee, and was the first chair of FDA's Vaccines ant! Related Biological Products Advisory Committee. In addition, he has served as President of both the Infectious Disease Society of America and the American Epidemiological Society. 43
44 CDC ANTHRAX VA CCINE SAFETY & EFFICA CY RESEARCH PROGRAM Patricia Ferrieri, M.D., is Professor of Laboratory Medicine ant! Pathology, ant} Pediatrics, anct Director of the Clinical Microbiology Laboratory at the University of Minnesota Mectical School. Her research interests include protein antigens of Group B streptococci, pathogenesis of infection, ant! host immunity. in acIdition, she is involved in molecular epidemiology, neonatal infections, and bacterial vaccines. She is a former chair of the FDA Vaccines ant} Related Bio- logical Products Advisory Committee, anti is knowleclgeable in regulatory and licensing proce- dures. Emi! C. Gotschlich, M.D., is Vice President for Medical Sciences at The Rockefeller Univer- sity, where he is also R. Gwin Follis-Chevron Professor and head of the Laboratory of Bacterial Pathogenesis and Immunology. His early work led to the development of a vaccine for preven- tion of groups A and C meningococcal meningitis. His research has also been directed at surface structures responsible for pathogenicity of gonococci and group B streptococci. Dr. Gotschlich is a fellow of the American Academy of Microbiology and a member of both the National Acad- emy of Sciences ant! the Institute of Medicine. Maurice Hilleman, Ph.D., D.Sc., serves as Director, Merck Institute, where he has spent 42 years. As a virologist-infectious disease scientist, Dr. Hilleman has been engages} in broad- spectrum programs in basic research discovery in virology anti viral immunology and in targeted research which has yielded a large number of vaccines, including vaccines for measles, mumps, rubella, varicelIa and combined MMR, pneumococcus, meningococcus, H. influenzoe, hepatitis A, and hepatitis B that are now used routinely. His most recent work has focused on vaccine de- velopment, improvement, and application, with emphasis on public health policy and worldwide utilization. He engages in summary simplification of the molecular biology, pathogenesis, epi- demiology, and immune prophylaxis of a number of viral infections. Other interests inclucle AIDS, hepatitis, virus in cancer, immunology, vaccinology, public policy, and Florid health ap- plications. Dr. Hilleman serves on the Committee to Review Research Proposals from Former Soviet Biological Weapons Institutes for the National Research Council Office of International Affairs and the U.S. Civilian Research ant} Development Foundation (CRDF), as well as a mem- ber of both the National Academy of Sciences and the Institute of Medicine. Dennis Kasper, M.D., is Executive Dean for Academic Programs, William Ellery Channing Professor of Medicine and Professor of Microbiology ant} Molecular Genetics at Harvard Mecti- cal School. He also serves as Director of the Channing Laboratory and as a senior physician at Brigham and Women's Hospital. With his colleagues ant! students, Dr. Kasper studies the mo- lecular basis of bacterial pathogenesis, applying the resulting knowle(lge to enhance unclerstand- ing of the interactions of bacterial surface virulence factors with host defenses. Dr. Kasper's studies focus on the molecular and chemical characterization of bacterial structures such as cap- sular polysaccharides, surface proteins, and toxins. The ultimate goal of this research is to cle- velop vaccines to prevent bacterial infections, notably those with group B streptococci. Regina Rabinovich, M.D., M.P.H., is Director, Malaria Vaccine Initiative, at the Program for Appropriate Technology in Health (PATH). Previously she served as Chief of the Clinical and Regulatory Affairs Branch and the Clinical Studies Section of the Division of Microbiology anct Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Rabinovich currently serves on the TOM Committee on a Strategy for Minimizing the Impact of Naturally Occurring Infectious Diseases of Military Importance: Vaccine Issues in the U.S. Military. In the past she served as the NTH liaison to the Centers for Disease Control Com-
APPENDIXB 45 mittee on Immunization Practices and the chair of the Epidemiology Section of the American Academy of Pediatrics. Brian L. Strom, M.D., M.P.H., is Chair and Professor of Biostatistics & Epidemiology, Profes- sor of Medicine, Professor of Pharmacology, Director of the Center for Clinical Epidemiology & Biostatistics, and Chair of the Graduate Group in Epidemiology & Biostatistics, all at the Uni- versity of Pennsylvania School of Medicine. His clinical and research training are in internal medicine, clinical pharmacology, and epidemiology, with a major research interest in the field of pharmacoepidemiology. He holds editorial positions on numerous journals, and has authored over 280 original papers as well as one of the first textbooks in the field. Dr. Strom has served as President of the International Society of Pharmacoepidemiology and as a member of the Board of Regents of the American College of Physicians, and is now on the Board of Directors for the American College of Epidemiology. He served on both the Medication Use Task Force of the Joint Commission on the Accreditation of Health Care Organizations, and the Drug Utilization Review Advisory Committee on the United States Pharmacopoeia Convention. He was elected to the American Society for Clinical Investigation, the American Epidemiologic Society, and the Association of American Physicians. Hugh H. Tilson M.D., Dr.P.H., is Clinical Professor of Epidemiology and Health Policy and Senior Advisor to the Dean at the University of North Carolina School of Public Health. Dr. Til- son is a practicing epidemiologist and outcomes researcher, with a career in preventive medicine and public health which spans more than 30 years and includes service as a director of both state and local health departments, and as Vice President for Worldwide Epidemiology, Surveillance, and Policy Research at GlaxoWellcome. He is an author of over 100 papers in the field of epi- demiology, outcomes and policy research, and public health; a fellow of the American College of Epidemiology, and a former vice-chair of the American Board of Preventive Medicine. Dr. Til- son also served as President of the American College of Preventive Medicine from ~ 995 to ~ 997 and was Founcling Co-President of the International Society for Pharmacoepidemiology. He serves regulatory and government agencies as well as pharmaceutical companies as an advisor and consultant in health outcomes, drug safety, and evidence-based health policy.